The Race To Develop A COVID-19 Vaccine: The Finish Line Approaches

A Visual Guide And Q&A On The Frontrunners

09 Oct 2020

• By Scrip Team

Updated: a graphic tracker of key developments from the leading vaccine candidates.

When will a vaccine against COVID-19 be ready? That's what everybody wants to know, because without one, the world remains at the mercy of the SARS-CoV-2 pandemic.

After an unprecedented surge of rapid vaccine development work over the course of 2020, there are today around 40 of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.